{"id":"tobramycin-once-a-day","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Nephrotoxicity (acute kidney injury)"},{"rate":"3-14","effect":"Ototoxicity (hearing loss, tinnitus, vertigo)"},{"rate":"rare","effect":"Neuromuscular blockade"},{"rate":"1-5","effect":"Injection site reactions"},{"rate":"1-3","effect":"Nausea and vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tobramycin irreversibly binds to the 30S ribosomal subunit of susceptible bacteria, disrupting accurate mRNA translation and causing misreading of the genetic code. This results in production of non-functional proteins and ultimately bacterial cell death. The once-daily dosing regimen takes advantage of the concentration-dependent bactericidal activity and post-antibiotic effect of aminoglycosides.","oneSentence":"Tobramycin is an aminoglycoside antibiotic that binds to bacterial 30S ribosomal subunits and inhibits protein synthesis, leading to bacterial cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:04.887Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus, Providencia, Citrobacter)"},{"name":"Cystic fibrosis-associated Pseudomonas aeruginosa lung infections"},{"name":"Gram-positive infections in combination with other antibiotics"}]},"trialDetails":[{"nctId":"NCT03935828","phase":"PHASE2","title":"Effect of Topical Sinonasal Antibiotics","status":"WITHDRAWN","sponsor":"United States Naval Medical Center, San Diego","startDate":"2019-06","conditions":"Chronic Rhinosinusitis (Diagnosis), Antibiotic Side Effect","enrollment":""},{"nctId":"NCT06106789","phase":"","title":"A Study of the Clinical Benefit of Tobramycin Inhalation Solution","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2023-04-01","conditions":"Bronchiectasis, Cystic Fibrosis, Lung Infection","enrollment":1600},{"nctId":"NCT06200727","phase":"NA","title":"Platelet-rich Fibrin(PRF) Membrane in Ophthalmic Diseases","status":"UNKNOWN","sponsor":"Lei Du","startDate":"2023-01-01","conditions":"Platelet-rich Fibrin, Macular Holes, Pterygium","enrollment":170},{"nctId":"NCT02918409","phase":"PHASE4","title":"IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2016-08-26","conditions":"Cystic Fibrosis","enrollment":51},{"nctId":"NCT01315678","phase":"PHASE3","title":"Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2012-02-29","conditions":"Pseudomonas Aeruginosa Infection","enrollment":302},{"nctId":"NCT04342507","phase":"NA","title":"Probiotics for Treatment of Chalazion in Adults","status":"COMPLETED","sponsor":"University of Molise","startDate":"2019-02-01","conditions":"Chalazion","enrollment":20},{"nctId":"NCT02657473","phase":"PHASE2, PHASE3","title":"Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis","status":"COMPLETED","sponsor":"Medical Center Alkmaar","startDate":"2016-08-13","conditions":"Non-CF Bronchiectasis","enrollment":58},{"nctId":"NCT03715322","phase":"PHASE3","title":"Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa","status":"UNKNOWN","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2018-10-26","conditions":"Bronchiectasis Adult, Pseudomonas Infections","enrollment":350},{"nctId":"NCT01570192","phase":"PHASE2","title":"Clinical Trials to Reduce the Risk of Antimicrobial Resistance","status":"TERMINATED","sponsor":"University of Florida","startDate":"2010-09","conditions":"Bacterial Pneumonia","enrollment":43},{"nctId":"NCT02015663","phase":"PHASE4","title":"Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-01","conditions":"Cystic Fibrosis","enrollment":32},{"nctId":"NCT02269969","phase":"PHASE1, PHASE2","title":"Once Daily Aminoglycoside Pharmacokinetics and Optimal Dosing in the Burn Population: A Prospective Study","status":"COMPLETED","sponsor":"Sandra Walker","startDate":"2015-03","conditions":"Burns, Infection","enrollment":10},{"nctId":"NCT00083551","phase":"PHASE3","title":"UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"1998-08","conditions":"Multiple Myeloma","enrollment":668},{"nctId":"NCT01207245","phase":"PHASE4","title":"Circadian Rhythm In Tobramycin Elimination In Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2011-05","conditions":"Cystic Fibrosis","enrollment":18},{"nctId":"NCT00774072","phase":"PHASE2","title":"Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization","status":"COMPLETED","sponsor":"University of Jena","startDate":"2008-10","conditions":"Cystic Fibrosis, Pseudomonas Aeruginosa","enrollment":9},{"nctId":"NCT00105469","phase":"PHASE3","title":"Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-07","conditions":"Bacterial Conjunctivitis","enrollment":743},{"nctId":"NCT01608555","phase":"PHASE4","title":"Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Milan","startDate":"2012-01","conditions":"Cystic Fibrosis","enrollment":10},{"nctId":"NCT01102244","phase":"PHASE3","title":"A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-04","conditions":"Blepharitis","enrollment":122},{"nctId":"NCT00257790","phase":"PHASE4","title":"The Tobramycin Study","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2001-09","conditions":"Neutropenia, Fever, Cancer","enrollment":210},{"nctId":"NCT00153634","phase":"NA","title":"Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2004-03","conditions":"Cystic Fibrosis, Chronic Bronchitis","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tobramycin once a day","genericName":"Tobramycin once a day","companyName":"Oslo University Hospital","companyId":"oslo-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tobramycin is an aminoglycoside antibiotic that binds to bacterial 30S ribosomal subunits and inhibits protein synthesis, leading to bacterial cell death. Used for Serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus, Providencia, Citrobacter), Cystic fibrosis-associated Pseudomonas aeruginosa lung infections, Gram-positive infections in combination with other antibiotics.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}